ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will highlight the LifeVest® Wearable Defibrillator in Booth #B9 at the European Society of Cardiology Heart Failure Congress 2014 from 17-20 May in Athens, Greece.
The LifeVest will be discussed during the following scientific sessions:
• Nicole Bianco, PhD, ZOLL, will present “Wearable Cardioverter Defibrillator Use for Short-Term SCA Protection in Patients with Preserved LVEF Heart Failure,” Saturday, 17 May, 8:30 am., Poster Session 1, Poster Area.
• Chingping Wan, MD, ZOLL, will present “Use of the Wearable Cardioverter Defibrillator in Patients with Infiltrative Disorders,” Tuesday, 20 May, 8:30 am., Rapid Fire Abstract Session, Agora Lecture Room.
Heart failure (HF) affects an estimated 15 million people in Europe.1 Patients newly diagnosed with HF have a high mortality rate, up to 40% in the first year, including a high risk of sudden cardiac death (SCD).2 Compared to the general population, SCD occurs 6-9 times more frequently in HF patients, 3 and an acute event such as hospitalization for heart failure decompensation or myocardial infarction increases the SCD risk.4,5 Likewise, an HF patient’s condition can improve from the benefits of optimized medical therapy, which can require up to 3 months or more to stabilize.6
The LifeVest is worn by patients at risk for SCD, including patients with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest provides protection during their changing condition and while permanent SCD risk has not been established, allowing a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, and before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
About Asahi Kasei
ZOLL Medical Corporation, an Asahi Kasei Group company (asahi-kasei.co.jp), develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
Copyright © 2014 ZOLL Medical Corporation. All rights reserved. AED Pro, AutoPulse, Code-Ready, IVTM, Real CPR Help, R Series, RescueNet, See-Thru CPR, X Series, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
2. O’Connor C, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Amer Heart J 2008;156:662-73.
3. Rosamond et al., Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008;117: e25 146.
4. Adabag AS, Therneau TM, Gersh BJ, et al. Sudden Death After Myocardial Infarction. JAMA 2008;300:2022-2029.
5. Solomon SD, Zelenkofske S, McMurray JV, et al. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. NEJM 2005;352:2581-2588.
6. Hall SA, et al. Time Course of Improvement in Left Ventricular Function, Mass and Geometry in Patients With Congestive Heart Failure Treated With Beta-Adrenergic Blockade. JACC 1995;25:1154-61.